Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER: TIP vs TI-CE as First Salvage in Relapsed/Refractory Germ Cell Tumors
2024-513509-30-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised trial of paclitaxel, ifosfamide, cisplatin, carboplatin and etoposide in germ cell tumor (GCT) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Planned start Aug 2024; status: authorised.
02
Drugs
paclitaxelifosfamidecisplatincarboplatinetoposide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2024-513509-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513509-30-00.